Test Background NSE is a glycolytic enzyme enolase (2-phospho-D-glyceratehydrolase) normally present in neurones, peripheral nerve tissues and neuroendocrine tissues, especially in the cells of the Amine Precursor Uptake Decarboxylation (APUD) system. It is in the form of dimers αγ and γγ with a molecular weight of approximately 95 kDa. Elevated levels occur in tumours of neuroectodermic or neuroendocrine origin, namely small-cell carcinoma of the lungs (SCLC), neuroblastoma, medullary thyroid carcinoma, carcinoid tumours, pancreatic endocrine tumours, seminoma and melanoma. Moderate elevations are also seen in some colorectal and breast cancers, and in patients with benign lung diseases.
Clinical Indications Lung cancer
Reference Range ≤16.3 µg/L
Sample Required SST (gold top) preferred, serum (red top) accepted
Sample Volume 0.5 mL
Samples should be stored at -20oC within 24 hours of separation. Send samples frozen.
Turnaround Time 4 weeks
Roche Cobas E411 method.
As NSE is present in erythrocytes, plasma cells and platelets, serum or plasma must be separated from red cells within 60 minutes of venepuncture to avoid spuriously high results.
Falsely low results may be obtained for this test due to biotin interference. Samples should not be taken from patients receiving therapy with high biotin doses (>5 mg/day) until at least 8 hours (ideally 2 days) following the last biotin administration.
Haemolysed samples are not suitable for analysis.